Fiona Blackhall

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer

  Cancer Discovery · 2026-06-22

• Evolutionary characterization of lung cancer metastasis

  Nature · 2026-04-29 · 3 citations

• Small-cell lung cancer: anatomy of an immune-cold tumor

  Trends in cancer · 2025-12-08 · 2 citations

• CO169 Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  Value in Health · 2025-12-01

• Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction

  Cell · 2025-11-07 · 13 citations

• EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

  European Journal of Cancer · 2025-10-30

• Matching-Adjusted Indirect Treatment Comparison of Tarlatamab Versus Comparator Therapies in England in Patients with Extensive-Stage Small Cell Lung Cancer Who Have Received Two or More Prior Lines of Therapy

  Advances in Therapy · 2025-10-08

• State of the art in treatment of small cell lung cancer

  Therapeutic Advances in Medical Oncology · 2025-09-01 · 3 citations

• 1992P Targeting KRAS codon 13 mutations using combinations with RMC-8839, a novel RAS(ON) G13C-selective, tri-complex inhibitor, in non-small cell lung cancer

  Annals of Oncology · 2025-09-01 · 1 citations

• Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis

  European Journal of Cancer · 2025-06-25 · 8 citations

• Circulating Tumor Cells Shed Shearosome Extracellular Vesicles in Capillary Bifurcations That Activate Endothelial and Immune Cells

  Advanced Science · 2025-06-09 · 9 citations

• Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

  Journal of Clinical Oncology · 2025-06-04 · 9 citations

• Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

  New England Journal of Medicine · 2025-06-02 · 183 citations

• Analysis of socio-economic deprivation and cancer trial participation.

  Journal of Clinical Oncology · 2025-05-28

• 4299 External reproduction of a causal estimation of the individual and cohort benefit of sequential vs concurrent chemoradiotherapy in SIII NSCLC patients

  Radiotherapy and Oncology · 2025-05-01

• Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer

  Cell Reports · 2025-04-29 · 7 citations

• Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy

  European Journal of Cancer · 2025-04-15 · 7 citations

• Challenges of small cell lung cancer heterogeneity and phenotypic plasticity

  Nature reviews. Cancer · 2025-04-10 · 39 citations

• Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 Trial

  Advances in Therapy · 2025-03-03 · 11 citations

• First-line osimertinib compared to earlier generation TKIs in advanced EGFR-mutant NSCLC: A real-world survival analysis

  Lung Cancer · 2025-01-09 · 5 citations